Jones, R; Sheehan, B; Phillips, P; Juszczak, E; Adams, J; Baldwin, A; Ballard, C; ... DOMINO-AD team; + view all Jones, R; Sheehan, B; Phillips, P; Juszczak, E; Adams, J; Baldwin, A; Ballard, C; Banerjee, S; Barber, B; Bentham, P; Brown, R; Burns, A; Dening, T; Findlay, D; Gray, R; Griffin, M; Holmes, C; Hughes, A; Jacoby, R; Johnson, T; Jones, R; Knapp, M; Lindesay, J; McKeith, I; McShane, R; Macharouthu, A; O'Brien, J; Onions, C; Passmore, P; Raftery, J; Ritchie, C; Howard, R; DOMINO-AD team; - view fewer (2009) DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease - a multicentre RCT. Trials , 10 , Article 57. 10.1186/1745-6215-10-57.

Preview

PDF 1745-6215-10-57.pdf Download (300kB)

Abstract

Alzheimer's disease (AD) is the commonest cause of dementia. Cholinesterase inhibitors, such as donepezil, are the drug class with the best evidence of efficacy, licensed for mild to moderate AD, while the glutamate antagonist memantine has been widely prescribed, often in the later stages of AD. Memantine is licensed for moderate to severe dementia in AD but is not recommended by the England and Wales National Institute for Health and Clinical Excellence. However, there is little evidence to guide clinicians as to what to prescribe as AD advances; in particular, what to do as the condition progresses from moderate to severe. Options include continuing cholinesterase inhibitors irrespective of decline, adding memantine to cholinesterase inhibitors, or prescribing memantine instead of cholinesterase inhibitors. The aim of this trial is to establish the most effective drug option for people with AD who are progressing from moderate to severe dementia despite treatment with donepezil.

Download activity - last month

Export as XMLCSVJSON

Download activity - last 12 months

Export as CSVXMLJSON

Downloads by country - last 12 months

Export as JSONXMLCSV

Archive Staff Only

View Item